Early family donor transplant for higher-risk myelodysplastic syndrome
Part of Blood & lymphatic clinical trials.
This trial looks at using a family donor transplant right away for people with higher-risk myelodysplastic syndrome (MDS). The goal is to see if this early transplant is safe and helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 to 70 years old.
- A matched sibling or family haplo-identical donor is available.
- Your MDS is classified as intermediate-2 or high risk, or has certain high-risk features like fibrosis or poor-risk genetics.
- You are well enough for a transplant: overall good physical condition (ECOG ≤ 2), heart function adequate (ejection fraction > 50%), and no serious uncontrolled infections.
- Your liver and kidney function meet minimum standards: certain blood tests within limits and creatinine clearance ≥ 30 ml/min.
- If using a haplo donor, you must not have specific antibodies against the donor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant that uses specially selected cells (CD34+ cells) to treat myelodysplastic syndrome (MDS), a blood disorder. The transplant comes from a donor and aims to replace unhealthy blood-forming cells with healthy ones, which may slow or stop the disease. It is designed for patients with higher-risk MDS or certain high-risk features.
This trial compares getting a stem cell transplant right away versus getting other treatments first before transplant for people with high-risk myelodysplastic syndrome (MDS), a bone marrow disorder. It aims to see which approach leads to better outcomes.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This trial tests a less intense chemotherapy and radiation combination (called TMLI, fludarabine, and melphalan) before a stem cell transplant from a matched donor. The goal is to help prepare your body for the transplant while reducing side effects, so it may be a good option if you have high-risk MDS or AML and cannot tolerate the standard, more intensive conditioning regimen.
This study looks at a personalized lab test to detect small amounts of disease after a stem cell transplant and then decide what treatment comes next. It may help some people with certain bone-marrow diseases stay in remission while avoiding unnecessary treatment.
This trial tests a conditioning regimen that is adjusted by age for people with low- or intermediate-risk myelodysplastic syndromes (MDS) who are receiving a half-matched (haploidentical) stem cell transplant from a family donor. The goal is to see if an age-stratified approach can improve outcomes.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.